GHK-Cu side effects and risks

Reported side effects

• Topical skin reaction: 1/40, 2.5%, stopped in the 8 week serum trial; reacted on both active and comparator sides., mild. Stop the product if irritation persists; the responsible ingredient was uncertain. (source)
• Darkening after needling plus serum: 8/20, 40%, versus 0/20 with needling alone in a nonrandomized acne scar study., moderate. Stop further application and have new or worsening pigmentation assessed. (source)
• Injection burning, bumps or bruising: Community reports only; no denominator or reliable incidence., moderate. Persistent, hot or spreading reactions need assessment; do not assume they are normal. (source)
• Nausea, dizziness or flushing: Reported after injections or blends; no controlled rates and no proven ingredient attribution., moderate. Stop exposure and seek assessment if symptoms persist or worsen. (source)
• Excess-copper organ injury: A copper toxicity risk; no GHK Cu specific incidence or safe injection threshold is established., serious. Stop and seek urgent care for jaundice, severe vomiting, confusion or reduced urine. (source)
• Immune reactions to impurities or aggregates: FDA identifies this potential risk for injectable GHK Cu; frequency is unknown., serious. Emergency care for breathing trouble, throat swelling or collapse. (source)

Stop and get help if

• Trouble breathing, throat swelling or collapse after use: Stop use and call emergency services now.
• Fever with spreading hot redness, pus or rapidly worsening injection pain: Stop injections and get urgent medical assessment for infection.
• Severe vomiting, abdominal pain, jaundice, confusion or much less urine: Stop exposure and get urgent care. Bring the product and dose history for possible copper toxicity.

Who should avoid it

• pregnant: No pregnancy safety data; pregnant people are excluded from the wound trial.
• breastfeeding: No infant-exposure or breastfeeding safety data; the wound trial excludes breastfeeding.
• tryingToConceive: Reproductive safety is unknown. The wound trial requires contraception through day 21.
• under18: No pediatric dosing or safety evidence. The registered wound trial starts at age 18.
• other: Copper overload can damage the liver and brain. Added copper is unsuitable without specialist direction.
• other: Avoid after a confirmed allergy to copper-peptide preparations or their ingredients; trial participants with these allergies are excluded.
• activeCancer: Precaution: it raises growth and blood-vessel signals in cells. Human cancer safety is unknown.
• cancerHistory: Cancer recurrence risk has not been studied; growth-signal findings warrant review.
• liverDisease: Copper leaves mainly through bile. Cholestasis or cirrhosis can reduce clearance; GHK-Cu dosing is unstudied.
• kidneyDisease: Systemic GHK-Cu safety is unstudied. Severe copper toxicity can involve the kidneys.
• diabetes: Diabetic wounds need infection checks and pressure relief; a cosmetic serum cannot replace wound care.
• immunosuppressed: Infection and wound-healing risks need review, especially with injections or needling.
• surgeryPlanned: Discuss use with the procedural team; post-laser benefit was not objectively demonstrated.
• testedAthlete: Systemic use falls under the inferred S0 unapproved-substance rule; confirm cosmetic use with the anti-doping authority.

Interactions

• Copper chelators: Added copper conflicts with copper-removal treatment. No direct GHK-Cu interaction study exists.
• Copper supplements or other copper preparations: These add copper exposure. Safe combined exposure with injected GHK-Cu has not been established.
• High-dose zinc: Zinc blocks gut copper absorption and excess can cause copper deficiency. It is not a proven safeguard against injected copper.
• Other peptide blends: Users stack these for repair. Combined safety, compatibility and sterility are not established.
• Anticoagulants during needling or injections: Needling and injections can bruise or bleed; this is a procedure risk. The acne-scar study excluded anticoagulant users.

Product quality risks

• FDA identifies peptide impurities and aggregation as potential immune risks for injectable GHK-Cu.
• Unapproved peptide products may have inaccurate contents or lack sterility; Health Canada and TGA warn about these risks.
• A purity percentage cannot show the dose per vial, sterility, endotoxin burden or exact copper-binding state.
• No independent human-use market survey of GHK-Cu vial identity, content and sterility was confirmed.